Sevion Therapeutics, Inc. (OTCMKTS:SVON) Files An 8-K Regulation FD Disclosure

Sevion Therapeutics, Inc. (OTCMKTS:SVON) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure

On June 26, 2017, Sevion Therapeutics, Inc. issued a press
release announcing the closing of a $6 million investment into
Eloxx Pharmaceuticals, Ltd. The Company is furnishing a copy of
the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instructions B.2 and B.6 of Form 8-K,
the information included in Item 7.01 of this Current Report on
Form 8-K (including Exhibit 99.1 attached hereto), shall not be
deemed filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference into any filing made by the
Company under the Exchange Act or the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
reference in such a filing.

Item 9.01. Financial Statements and
Exhibits.

(d)Exhibits.

Exhibit Number

Description

99.1 Press Release dated June 26, 2017.



Sevion Therapeutics, Inc. Exhibit
EX-99.1 2 v469827_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1         ELOXX PHARMACUETICALS RECEIVES A US$6 MILLION INVESTMENT FROM KIP and DCS TO ADVANCE A NOVEL DISEASE-MODIFYING THERAPY TARGETING GENETIC DISEASES INCUDING CYSTIC FIBROSIS   San Diego,…
To view the full exhibit click here
About Sevion Therapeutics, Inc. (OTCMKTS:SVON)

Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

An ad to help with our costs